Atlas Trials

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Clinical trial NCT02750670 · COMPLETED

Trial details

NCT number
NCT02750670
Sponsor
University Health Network, Toronto
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Lymphoma, Non-Hodgkin's
Start date
2017-03-15
Primary completion
2020-09-09
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.